抗干素33治疗缓解了小鼠诱导的伊米基莫德皮肤炎
Dandan Fu1, Shuting Zheng1, Jialin Li1
1Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China.
International immunopharmacology
|June 21, 2023
概括
在牛皮的小鼠模型中,抗素-33 (IL-33) 抗体治疗减少了皮肤炎症和免疫细胞透. 这表明IL-33是牛皮的潜在治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 炎症研究 炎症研究
背景情况:
- 介素-33 (IL-33) 在皮肤上皮细胞中表达,并与牛皮的严重程度有关.
- 牛皮是一种慢性炎症性皮肤疾病,其特点是红血症,化和表皮质增生.
研究的目的:
- 为了研究抗IL-33抗体的治疗潜力,在皮性皮肤炎的伊米奎莫德诱导的小鼠模型中.
- 评估抗IL-33抗体对临床症状,免疫细胞透和牛皮关键分子通路的影响.
主要方法:
- 建立了一种因伊米基莫德诱导的牛皮皮炎小鼠模型.
- 用抗IL-33抗体治疗小鼠,并评估治疗效果.
- 分析了皮肤病变,指数,细胞因子表达,免疫细胞群 (Ki-67,CD3+CD4+T细胞,CD3+CD8+T细胞) 和STAT3酸化.
主要成果:
- 抗IL-33抗体显著改善了红血热,脱落,表皮厚度和脏指数.
- 治疗减少了牛皮相关细胞因子的表达,并抑制了皮肤病变中的淋巴细胞透 (Ki-67,CD3+CD4+T,CD3+CD8+T细胞).
- 在模型小鼠中,抗IL-33抗体下调调节了STAT3酸化和IL-33表达.
结论:
- 在牛皮的小鼠模型中,抗IL-33抗体有效地减轻了皮肤病变,并抑制了关键的炎症途径.
- 这些发现表明,IL-33在牛皮皮炎的发病过程中起着至关重要的作用.
- 用抗体向IL-33代表了治疗牛皮的有希望的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158


